Saved Results

No results saved yet.

Enter a patient name and hit Save on a result.

Clinical calculator summary

Leibovich Score for Renal Cell Carcinoma

The 2003 Leibovich score predicts metastasis-free survival after nephrectomy using pathological variables from clear-cell RCC.

Evidence-based context for fast calculator use

Purpose:
Risk stratification for metastatic progression after nephrectomy for localized or locally advanced clear-cell RCC
Population:
Sporadic, unilateral pT1-4 N0/+ M0 clear-cell RCC after nephrectomy, assessed using 2002 TNM and Fuhrman grade
Factors:
2002 pathologic T category, Regional lymph node status, Tumor size, Fuhrman nuclear grade, Histologic tumor necrosis
Reference:
Leibovich et al., Cancer 2003; DOI 10.1002/cncr.11234
HomeLeibovich Score (RCC)
Pin your most used calculators here by clicking the star in the dropdown.

Leibovich Score (RCC)

cm

Clinical Context & Background

The 2003 Leibovich model is for sporadic, unilateral, non-metastatic (M0) clear-cell renal cell carcinoma after nephrectomy. It uses 2002 AJCC pathologic T and N categories, tumor size, Fuhrman nuclear grade, and histologic tumor necrosis. It is not the 2018 Leibovich model and should not be applied to metastatic or non-clear-cell RCC.
Primary Source EvidenceLeibovich BC, Blute ML, Cheville JC, et al. Cancer. 2003;97(7):1663-1671. DOI: 10.1002/cncr.11234.
Formula Logic
pT points + pN points + size points + Fuhrman grade points + necrosis points. pT1a=0; pT1b=2; pT2=3; pT3a-pT4=4. pNx/pN0=0; pN1/pN2=2. Size <10 cm=0; ≥10 cm=1. Grade 1-2=0; grade 3=1; grade 4=3. Necrosis absent=0; present=1.

Reference Data

Risk GroupScore5-Year MFS10-Year MFS
Low risk0-297.1%92.5%
Intermediate risk3-573.8%64.3%
High risk≥631.2%23.6%

Clinical Workflow

Use, Interpret, And Continue The Patient Pathway

Expand for workflow guidance, limitations, examples, and related next steps.

When To Use

  • Use after nephrectomy when final pathology confirms sporadic, unilateral, M0 clear-cell renal cell carcinoma.
  • Use the original 2002 TNM categories and Fuhrman grade required by the 2003 model.
  • Use for recurrence-risk communication and risk-adapted surveillance discussions, alongside current clinical guidance.

How To Interpret

  • Scores 0-2 are low risk, 3-5 intermediate risk, and 6-11 high risk.
  • Published 5-year metastasis-free survival was 97.1%, 73.8%, and 31.2% for these groups, respectively.
  • Published 10-year metastasis-free survival was 92.5%, 64.3%, and 23.6%, respectively.

What To Do Next

  • Document the score and every pathology variable used so the assessment is reproducible.
  • Choose surveillance using current RCC guidance and the complete clinical context, not the score alone.
  • For metastatic RCC, use an appropriate metastatic model such as IMDC rather than Leibovich 2003.

Limitations

  • Do not use for metastatic disease, non-clear-cell histology, bilateral or hereditary RCC, or patients without definitive postoperative pathology.
  • The derivation model used 2002 TNM and Fuhrman grade; current TNM and WHO/ISUP grade are not automatically interchangeable inputs.
  • The published group estimates describe the original cohort and are not individualized treatment recommendations.

Validated Population

Patients with sporadic, unilateral pT1-4 N0/+ M0 clear-cell RCC treated by nephrectomy with complete 2002 TNM, Fuhrman grade, size, and necrosis data.

Example use

pT3a, pN0, 8 cm, Fuhrman grade 3 disease with necrosis scores 6 and is in the high-risk group (published 5-year MFS 31.2%).

Renal cancer calculator hubNavigate localized and metastatic RCC calculators together.IMDC metastatic RCC riskUse for metastatic RCC systemic-therapy prognosis.SSIGN RCC scoreCompare another post-nephrectomy RCC model.MSKCC/Motzer RCC scoreHistorical metastatic RCC prognostic model.

Calculation verification history

Verified

  1. : Production browser revalidation

    • Three source-backed cases passed through visible production controls at Leibovich scores 0, 3, and 11.
    • Low, Intermediate, and High groups rendered as expected.
    • No unexpected N/A, literal undefined value, stale control, unsupported gauge, or browser-console error was observed.
    Download latest production check (Excel)

    Case-level evidence is retained in validation/browser-revalidation/leibovich-prognostic-rcc-2026-08-03.json.

  2. : Production browser validation

    • Ten source-backed cases were exercised on the public production route through visible browser controls; 10/10 case records passed their expected-versus-observed assertions across 11 visible submissions.
    • Overall browser status: failed-console. medium: Production emitted minified React error #418 during route loads/reloads used by this run.
    • Case-level inputs, expected and observed results, reset/repeat behavior, failure reproductions, and console evidence are retained in the production-browser evidence record.

    Case-level production evidence is retained in validation/browser-production/leibovich-prognostic-rcc.json.

  3. : Full validation test

    • Passed 48/48 literal checks covering scores 0-11, every source category and boundary, and strict missing or invalid input behavior with zero difference.

  4. : Correction

    • Corrected pT4 to 4 points rather than 5.
    • Corrected source-group 5-year metastasis-free survival estimates to 97.1%, 73.8%, and 31.2%, and added the 10-year estimates 92.5%, 64.3%, and 23.6%.
    • Added a required positive numeric tumor-size input and rejected missing, extra, malformed, and out-of-domain inputs.

    Included in the current validation report.

Verification confirms the calculator implementation against the cited model; it is not independent clinical validation, regulatory approval, or medical advice.

Found a possible issue? Report it to improve this calculator

Share This Calculator

Share:

Related Tools

IMDC (Heng) Risk Criteria Calculator — Metastatic Renal Cell CarcinomaSSIGN Score (Mayo)MSKCC (Motzer) Score

Frequently Asked Questions

Which Leibovich model is this?

This calculator implements the 2003 model for non-metastatic clear-cell RCC, not the separate 2018 models.

Can Leibovich 2003 be used for metastatic or non-clear-cell RCC?

No. Its intended population is postoperative M0 clear-cell RCC; use a model validated for the relevant disease setting instead.

Which variables are required for the Leibovich score?

The 2003 model uses 2002 pathologic T and N categories, maximum tumor size, Fuhrman nuclear grade, and histologic tumor necrosis from the nephrectomy specimen.

What do the Leibovich risk groups mean?

Scores 0-2, 3-5, and 6-11 identify the original low-, intermediate-, and high-risk groups with published cohort estimates of metastasis-free survival. They are not individualized treatment predictions.

Can current WHO/ISUP grade be entered as Fuhrman grade?

Not automatically. The 2003 model was developed with Fuhrman grade, and a current WHO/ISUP grade should not be substituted without an appropriate pathology interpretation.

Evidence-based oncology decision support. Verify with clinical guidelines.